You just read:

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

News provided by

Sutro Biopharma, Inc.

Jun 15, 2019, 06:00 ET